Portal de Periódicos da CAPES

The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis

2017; Elsevier BV; Volume: 35; Issue: 3 Linguagem: Inglês

10.1016/j.det.2017.02.005

1558-0520

Jonathan I. Silverberg, Robert Kantor,

Allergic Rhinitis and Sensitization

Moderate to severe atopic dermatitis (AD) can be debilitating and often requires use of systemic immunosuppressant therapy to achieve adequate disease control. There are currently no US Food and Drug Administration-approved systemic agents for the long-term treatment of AD. Recent insight has identified the T helper 2 cytokines, interleukins 4 and 13, as playing a major role in the pathogenesis of AD. There are multiple novel biologic agents in development that target interleukins 4 and/or 13 for the treatment of moderate to severe AD. The age of targeted biologics for AD has arrived.